Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab vs ipilimumab vs cabazitaxel in metastatic castration-resistant prostate cancer
2022-502909-15-00Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Nivolumab plus ipilimumab, Ipilimumab monotherapy and Cabazitaxel plus prednisone (3 arms). Primary endpoints: Objective Response Rate in Cohorts B, C, and D and Radiographic Progression-Free Survival. Started Aug 2023; status: completed.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2022-502909-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502909-15-00.